- Home
- NWAX vs LAB Comparison
NWAX vs LAB Comparison
Compare NWAX & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWAX | LAB |
|---|---|---|
| Founded | 2025 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.0M | 488.4M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | NWAX | LAB |
|---|---|---|
| Price | $10.05 | $0.95 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 75.8K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.00 | $0.92 |
| 52 Week High | $10.25 | $1.72 |
Technical Indicators
Market Signals| Indicator | NWAX | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 31.33 |
| Support Level | $10.00 | N/A |
| Resistance Level | $10.10 | $1.41 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 50.00 | 12.60 |
Price Performance
Historical ComparisonAbout NWAX New America Acquisition I Corp. Class A Common Stock
New America Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to throughout this prospectus as its initial Business Combination.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.